Compare · DMRA vs NVO
DMRA vs NVO
Side-by-side comparison of Damora Therapeutics Inc. (DMRA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DMRA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 154.1x DMRA ($1.24B).
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for DMRA).
- NVO has more recent analyst coverage (25 ratings vs 5 for DMRA).
- Company
- Damora Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $1.24B
- $191.15B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 4
- 8
- Recent ratings
- 5
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DMRA
- H.C. Wainwright initiated coverage on Damora Therapeutics with a new price target
- TD Cowen initiated coverage on Damora Therapeutics
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Wedbush initiated coverage on Damora Therapeutics with a new price target
- SEC Form SCHEDULE 13G filed by Damora Therapeutics Inc.
- Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
- SEC Form 10-Q filed by Damora Therapeutics Inc.
- SEC Form 3 filed by new insider Burkavage Brian
- Damora Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care